CD28 and inflammatory bowel disease: In IBD, CEACAM1 was confirmed as a newly, non‐CD28‐associated co‐inhibitory receptor that mediated suppression of the T‐cell receptor–CD3 complex in a cell autonomous manner, and subsequently blocked the progression of intestinal inflammation.97